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Safety Issues in the Pharmacologic Management of 
Chronic Pain in the Elderly 
Leslie A. Shimp, Pharm.D. 
Chronic pain is commonly encountered in elderly patients. About 20-50% of 
community-dwelling elderly experience it, and 4540% of nursing home 
residents may be affected. Selection of pharmacologic therapy for the 
management of chronic pain must take into consideration the increased 
potential for adverse effects in this population. Major classes of drugs used to 
treat chronic pain (nonsteroidal antiinflammatory drugs,  opioids, 
antidepressants) have adverse effects that occur more frequently in elderly 
than in younger patients. Given the often prolonged duration of therapy, 
optimal management requires minimizing the risk of adverse reactions. 
(Pharmacotherapy 1998; 18(6): 13 13-1 322) 
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Conclusion 
The high number of prescriptions for analgesic 
agents attests to the prevalence of pain-related 
conditions. Prescriptions for nonsteroidal anti- 
inflammatory drugs (NSAIDs) in the United 
States increased from approximately 28 million 
in 1973 to 67 million in 1983 and have remained 
relatively constant since then.’ In 1991 approxi- 
mately 70 million NSAID prescriptions were 
filled,2 more than 40% for elderly patients3 In 
addition, significant quantities of nonprescription 
analgesics are consumed, with more than $900 
million worth purchased annually in the United 
 state^.^ With such widespread use, it is clear that 
safety issues associated with these agents arise, 
particularly when they are given to treat elderly 
patients. 
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Prevalence of Pain 
Approximately 80% of visits to physicians are 
for conditions with a pain component. According 
to the National Institutes of Health chronic pain 
is the third largest health problem in the world, 
and in 1982 it afflicted approximately 65 million 
American~.~ Common conditions are headache 
(40 million Americans suffer from chronic 
‘ recurrent headaches), low back pain (about 15% 
of adults experience chronic low back pain at 
some time during their lives), and arthritis 
(affecting 20 million Ameri~ans).~ 
Chronic pain conditions are particularly 
prevalent among the elderly, occurring twice as 
often in persons 65 years of age and older as in 
younger individuak6 As many as 20-50% of 
elderly people living in  the community 
experience chronic pain,7 and the figures are 
4540% for those in long-term care institutions.8 
This prevalence is largely due to disproportionate 
occurrence of conditions associated with chronic 
pain in this age group; for example, arthritis, 
which may affect as many as 80%, cancer, tic 
douloureux, and herpes zoster.*. * 
In addition to suffering, chronic pain takes a 
toll i n  terms of health care costs. I t  was 
estimated that the annual cost (both direct and 
indirect) in the United States is $50 b i l l i ~ n . ~  
Types of Pain 
Pain is defined as “an unpleasant sensory and 
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PAIN 
emotional experience associated with actual or 
potential tissue damage, or described in terms of 
such damage."' Chronic pain persists beyond the 
expected healing time''; according to the 
International Association for the Study of Pain, 3 
or more months after an injury." I t  is often 
associated with psychological or social factors, 
such as depression and anxiety, and other factors, 
such as disability and changes in personality 
(Figure 1>.8! lo 
Chronic pain can be categorized as nociceptive, 
neuropathic, or idiopathic.", l2 Nociceptive pain 
results from continuing damage to soft or bony 
tissues and is characterized by a localized, sharp, 
or aching quality. The nervous system is intact 
and pain is experienced secondary to tissue 
damage. Chronic pain associated with arthritis 
and cancer is classified as nociceptive. Neuro- 
pathic pain occurs after damage to or pressure on 
nerves or neural tissue of the central or periph- 
eral nervous system. Examples are postherpetic 
neuralgia, trigeminal neuralgia, diabetic 
neuropathy, and phantom limb pain. This type of 
pain typically follows the distribution of nerves 
and may be described as burning, tingling, pins 
and needles, deep aching, or numbness.  
Idiopathic pain has no underlying causk. More 
than one type of pain may be present in a patient 
with chronic pain. 
Distinguishing the type of pain can assist in 
selecting the appropriate therapy. Nociceptive 
pain is responsive to traditional analgesic agents 
(NSAIDs, opioids), but neuropathic pain is 
generally not. Although more difficult to treat, 
TOTAL 
PAIN 
Psychological Factors 
- anxiety 
- depression 
- social support 
- cultural factors 
Nociceptive pain , \ 
Neuropathic pain 
Idiopathic pain 
Other Factors 
- cognitive function 
- other physical symptoms 
- adverse drug effects 
- relationship with health 
care providers 
Figure 1 .  Factors contr ibut ing to chronic  pain and 
suffering. 
neuropathic pain may be relieved by adjunctive 
agents such as antidepressants and anticonvulsants. 
Treatment 
The goals of treating these patients are to 
determine the type of pain, relieve pain to the 
greatest extent possible, educate patients and 
family, and ensure maximum function and sense 
of autonomy and contrbl for the patient." 
Achieving these goals usually requires several 
pharmacologic and nonpharmacologic modalities. 
Applying both types is likely to result in greater 
pain control and reduce the risk of adverse drug 
effects.', l3 
Many clinicians stress the importance of 
differentiating between pain relief and resump- 
tion of function. It may be impossible to j-elieve 
chronic pain completely; rather, the goal should 
be to maintaisjthe patient's function, mobility, 
and a ~ t i v i t i e s . ' ~  In addition, these patients 
frequently experience anxiety and depression. It 
was estimated that 20-50% of have depressive 
symptoms that require treat men^^ Attention to 
these conditions is important because they may 
lower the pain threshold7. l4 or decrease the 
patient's functional status.8 
Treating elderly patients with chronic pain 
requires consideration of several additional 
factors including age-related alterations in pain 
sensation, cognitive status, and concurrent drug 
therapy. In a review of studies examining the 
perception of pain by the elderly, the authors 
concluded that no real consensus exists about 
age-related changes in pain perception. l5 The 
expectation that older patients will experience 
less pain is inappropriate and may result in 
undertreatment and reduction in quality of life.8 
In fact, these individuals may require specific 
attention to the presence and intensity of pain, 
the impact of pain on quality of life, and prompt 
and accurate diagnosis and treatment. The 
following are principles in managing pain in 
these patients': 
Always ask them about pain. 
.Accept their  word about pain and i ts  
intensity. 
Never underestimate the potential effects of 
chronic pain on a patient's overall condition 
and quality of life. 
Be rigorous in assessing pain; an accurate 
diagnosis will lead to the most effective 
treatment. 
Treat pain to facilitate diagnostic procedures; 
do not wait for a diagnosis before relieving it. 
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Use a combined approach of drug and non- 
drug strategies when possible. 
Mobilize patients physically and psychosocially, 
and involve them in therapy. 
Administer analgesic drugs correctly, starting 
with low dosages and increasing them slowly; 
achieve adequate dosages and anticipate side 
effects. 
Anticipate and attend to anxiety and 
depression. 
Reassess responses to treatment; alter therapy 
to achieve maximum functional status and 
quality of life. 
Cognitive status may influence therapy either 
by altering the amount or quality of information 
that the patient can supply or by limiting drug 
therapy due to adverse effects on cognition. 
Concurrent drug therapy also should be considered. 
Behavioral and psychosocial therapies are often 
incorporated into protocols and improve the 
response to analgesics. l6 Structured behavioral 
strategies, including psychologic counseling, 
relaxation techniques, and stress management, 
can provide therapeutic benefit.17 
Drug Therapy 
The choice of drugs is based on the type of 
pain and the patient's medical condition." 
Combinations of drugs often are appropriate, as 
they can provide synergistic action by relieving 
pain by different mechanisms or provide superior 
relief if more than one type of pain is present. 
Acetaminophen 
Acetaminophen is an effective analgesic for 
mild pain; when combined with opioid analgesics 
it can be given to manage more severe pain. It 
may be effective in patients with osteoarthritis. 
Its benefits compared with NSAIDs are a superior 
adverse effect profile (NSAIDs have increased 
frequency of toxicity in the elderly), significantly 
lower cost, and lack of potential to inhibit 
synthesis of proteoglycans, which are necessary 
for cartilage repair.l9> 2o 
In general, acetaminophen is a safe agent; 
however, excessive short-term doses (1 15 g in an 
adult) or long-term use (> 5 g/day) can cause 
hepatotoxicity (Table 1) .21-33 In addition, 
evidence suggests that long-term ingestion of 
ethanol may predispose individuals to 
acetaminophen-related h e p a t o t o x i ~ i t y . ~ ~ .  35 
Concern was raised regarding the potential for 
acetaminophen-induced hepatotoxicity after 
modest doses (4-10 g/24 hrs) during fasting 
conditions (e.g., viral illness with gastrointestinal 
symptoms, dehydration) .23 These issues must be 
considered when recommending acetaminophen 
to any patient. 
NSAIDs 
These drugs are useful for mild to moderate 
pain, particularly that of musculoskeletal origin 
or caused by inflammation or cancer.18 Although 
NSAIDs vary in duration of action and adverse 
effect profiles, their analgesic efficacy is similar. 
Their effect is apparent within 0.5-4 hours after 
oral administration, although antiinflammatory 
effects may not be manifested for several days to 
weeks.22 The NSAIDs appear to have a ceiling for 
analgesic effect beyond which a dosage increase 
does not provide increased relief.18- 36 Because 
this ceiling varies from patient to patient, slow 
dosage escalation can help determine this value.36 
Patients may respond differently to certain 
agents; therefore, a trial with another NSAID may 
be appropriate if the first one provides 
inadequate pain relief.37 
Although NSAIDs have a good overall safety 
profile, the sheer magnitude of their use puts 
them at the top of the list for serious adverse drug 
reactions in the United States and 2 5 3  38 In 
1985 a British study indicated that 25% of 
reported adverse reactions in men and 30% in 
women were attributed to these agents.25 In 1990 
the U.S. Food and Drug Administration imposed 
a class warning label because the risk of NSAID- 
induced ulcers and gastrointestinal bleeds was 
estimated to be 2 4 %  annually3' The drugs may 
cause a variety of adverse effects in the elderly, 
particularly gastrointestinal and renal toxicity. 
Gastrointestinal Toxicity 
The association between NSAIDs and gastro- 
intestinal toxicity is well established. The agents 
are linked to increased risk for gastric ulcers, 
duodenal ulcers, upper gastrointestinal hemor- 
rhage, and death from peptic ulcer disease or 
gastrointestinal 3942 Results of a 
meta-analysis estimated the overall odds ratio for 
the risk of adverse gastrointestinal events related 
to NSAIDs to be 2.74 (CI 2.54-2.97).39 The risk 
for a gastrointestinal-related hospitalization was 
estimated to be 6 times greater for patients with 
rheumatoid arthritis taking NSAIDs compared 
with those not taking the drugs.38 
Results of a case control study in  elderly 
patients reported similar findings.26 The 
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Table 1. Management of Common Adverse Effects of Analgesics 
Analgesic Adverse Effect Management 
Acetaminophen22, 2 3  Hepatotoxicity 
NSAIDS~.’~-’~ 
Avoid long-term administration of more than 4 g/d. 
Avoid when patient is ingesting limited food or consumes long-term ethanol. 
Give lowest effective dosage; periodically reassess required dosage. 
Begin therapy with drugs least likely to cause gastrointestinal toxicity 
Administer with misoprostol in at-risk patients. 
Periodically monitor for gastrointestinal blood by hematocrit and stool guaiac. 
Give lowest effective dosage; periodically reassess reqyired dosage. 
Avoid concurrent diuretics. 
Begin therapy with drugs least likely to cause renal toxicity (salsalate, 
Assess high-risk patients (renal function, electrolytes, weight) when therapy is 
Gastrointestinal toxicity 
(etodolac, ibuprofen, ketoprofen, nabumetone, naproxen). 
Renal toxicity 
sulindac); avoid fenoprofen, indomethacin, naproxen. 
begun and 2 wks later. 
Nausea, vomiting 
Constipation 
Sedation, dizziness Tramadol*. lo, 30. 32 
Traditional Sedation, confusion Tolerance usually develops; begin or increase dose in stepped doses; decrease 
Discontinue other therapy with potential additive adverse central nervous 
Switch to another opioid or decrease opioid dose and try combination therapy 
I 
Tolerance usually develops. 
Administer antinausea agents (cisapride,’ hydroxyzine, prochlorperazine) 
Increase dietary fluids and fiber. 
Administer laxative (stool softener, stimulant laxative; lactulose). 
opioids7, 8.10.30.31 dose and increase dosing frequency. 
system effects. 
with another type of analgesic. 
selected by mechanism of nausea. 
Tolerance usually develops. 
Begin or increase dose in stepped doses; decrease dose and increase dosing 
DisSontinue therapy with potential additive central nervous system effects. 
Switch to another opioid or decrease opioid dosage and give in combination 
frequency. 
with another type of analgesic. 
Nausea, vomiting Tolerance usually develops. 
Administer antinausea agents (cisapride, hydroxyzine, prochlorperazine) 
Increase dietary fluids and fiber. 
Administer laxative (stool softener, stimulant laxative; lactulose). 
selected by mechanism of nausea. 
Constipation 
Antidepressants”, 33 Sedation, delirium Avoid most sedating antidepressants (amitriptyline); give dose at bedtime. 
Discontinue other therapy with potential additive central nervous system 
Administer dose at bedtime. 
(dry mouth, decreased Switch to drug with weaker anticholinergic effects (desipramine, trazodone). 
visual accommodation, Discontinue other therapy with anticholinergic effects. 
constipation) Dry mouth: frequent sips of water, artificial saliva. 
Constipation: dietary fluids and fiber. 
Orthostatic hypotension Instruct patient about sudden shift in posture. 
Switch to drug with less potential for effect (desipramine, nortriptyline). 
Administer therapy for orthostatic hypotension (liberal sodium intake; 
effects. 
Anticholinergic effects 
fludrocortisone). 
estimated relative risk for developing peptic ulcer 
disease was 4.1 (CI 3.5-4.7) among NSAID users 
compared with control patients,  and the 
association with increased risk was consistent for 
subpopulations (e.g. ,  gender, race, age). 
Furthermore, the increased risk occurred for 
several other diagnoses including gastric ulcer 
(relative risk 5.5, CI 4.4-6.91, duodenal ulcer 
(relative risk 4.3, CI 3.5-5.2) ,  and upper  
gastrointestinal hemorrhage (relative risk 2.4, CI 
1.8-3.2). In a similar case control study, death 
from peptic ulcer disease and gastrointestinal 
hemorrhage was 4 times more likely in elderly 
patients currently taking NSAIDs than in elderly 
not taking them.42 
Risk Factors. Numerous patient characteristics 
are linked to an increased risk for gastrointestinal 
toxicity, including age, female gender, and history 
of gastrointestinal disease. The relative risk for 
SAFETY ISSUES IN MANAGING CHRONIC PAIN IN THE ELDERLY Shimp 1317 
serious gastrointestinal events was more than 3 
times greater among elderly than younger users.39 
Similarly, the hazard ratio for gastrointestinal 
death in  elderly patients (> 60 yrs) with 
rheumatoid arthritis and taking NSAIDs was 
almost 3 times greater than for younger 
patients.38 
Several reasons explain why the elderly, 
especially women, may be at greater risk for this 
type of toxicity. First, elderly patients have a 
high rate of exposure to the drugs because they 
have a high prevalence of chronic pain 
conditions. Specifically, elderly women may have 
greater exposure simply because they outnumber 
elderly men (particularly in  the oldest age 
groups), because of differences in prescribing 
(60% of NSAID users are women), or because 
certain painful conditions (e.g., rheumatoid 
arthritis) are more common in women.38* 40, 41 
The elderly, especially women, may be at greater 
risk by virtue of lower body weight; gastric ulcers 
appear to be related to systemic changes in 
prostaglandin production by NSAIDs, and the 
lower ratio of body mass to dose may amplify 
systemic effects.41 Furthermore, the greater 
prevalence of Helicobacter pylori gastritis in the 
elderly may be related to increased risk.41 
Certain characteristics of NSAIDs also may 
predispose select patients to gastrointestinal 
toxicity. The risk for peptic ulcer disease 
increases as NSAID dosage increases.39 Duration 
of therapy is inversely related to risk of related 
gastrointestinal toxicity. A compilation of data 
from 10 studies suggests that the risk is highest 
during the first 3 months of 39 This 
seemingly backward association is thought to be 
a result of mucosal adaptation that occurs after 
prolonged therapy.39. 41 Another explanation may 
be compliance; if compliance is better when 
therapy is begun, the risk may be greatest shortly 
after the drug is pre~cr ibed .~~ 
Variability among NSAIDs. Limited data suggest 
that the risks incurred with different agents may 
vary.26, 39 In two studies, ibuprofen was associated 
with the lowest risk for NSAID-related gastro- 
intestinal toxicity. In addition, reports of this 
condition were fewer for two relatively new 
agents, etodolac and nabumetone, which may 
pose less risk both with short- and long-term 
therapy.27 However, confidence intervals for 
various NSAIDs tend to be broad and over- 
lapping, and more studies are necessary to 
determine if differences in risk among agents 
truly exist. 
Renal Toxicity 
Renal toxicity is not  as frequent as 
ga~t ropa thy ,~~ occurring in perhaps as many as 
5% of persons taking an NSAID.44 However, by 
virtue of age-related changes in kidney function 
and concurrent drug therapy, the group most 
likely to be at risk is the elderly.24, 28, 29 T ypes of 
NSAID-induced renal toxicity include acute 
reversible renal failure; impaired renal excretion 
of sodium, potassium, and water; acute 
interstitial nephritis; and analgesic nephr~pathy .~~ 
Acute renal failure secondary to decreased 
vasodilatory prostaglandins is the most common 
form of NSAID-induced renal toxicity and is 
rapidly reversib1e.l' For most patients, even the 
elderly, these vascular effects are minimized by 
other forces.29% 43 However, the presence of 
disease or concurrent drugs may result in  
toxicity. 
Risk Factors. Patients susceptible to NSAID 
inhibition of prostaglandins include the elderly 
and those with volume depletion (e.g., diuretics), 
congestive heart failure, hepatic cirrhosis, 
diabetes mellitus, infections, and preexisting 
renal ins~f f ic iency .~~ Concurrent diuretic and 
NSAID therapy may decrease renal blood flow 
and glomerular filtration rate, and cause sodium 
retention. As a result, clinically important fluid 
accumulation may develop in  patients with 
congestive heart failure, arteriosclerotic heart 
disease, or renal impairment. A decline in renal 
function occurred in  20% of patients with 
arteriosclerotic heart disease who took a diuretic 
and an NSAID.29 Similarly, the actions of NSAIDs 
on  prostaglandins and renin may cause a 
clinically important elevation in  serum 
potassium, especially if the patient is 
concurrently receiving an angiotensin-converting 
enzyme inhibitor or potassium-sparing 
diuretic.24, 43 The likelihood of acute renal failure 
increases with higher NSAID dosages and 
perhaps with drug accumulation in the elderly 
because of impaired clearance resulting in greater 
prostaglandin effects.29, 43, 45 
In high-risk patients, all NSAIDs are likely to 
cause acute renal failure.29 In an elderly patient 
with chronic renal insufficiency, renal function 
deteriorated further in  the presence of three 
sequentially prescribed NSAIDs, sulindac,  
piroxicam, and ibuprofen.28 In patients with 
moderate risk (i.e., fewer or milder degrees of 
medical conditions noted above), either lower 
dosages or certain agents (e.g., salsalate, 
sulindac) may decrease the risk of NSAID- 
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induced nephr~pathy.~~,  43 In all elderly patients, 
therapy should be preceded by assessment of 
renal function, electrolytes, and weight; these 
measurements should be repeated 1-4 weeks 
after start of therapy3. 24, 29 
Both acute interstitial nephritis and analgesic 
nephropathy are rare forms of NSAID-induced 
renal toxicity. Duration of therapy is the only 
identified risk factor; this condition is reported 
most commonly with fenoprofen.2a, 37 
Traditional Opioid Analgesics 
Opioid analgesics are administered to treat 
moderate to severe pain. They are effective against 
all types of pain, although their effectiveness in 
neuropathic pain is limited.*, 30 Traditional 
opioid analgesics are generally classified as 
agonists, mixed agonist-antagonists, or partial 
agonists. This classification is based on their 
actions at three central opioid receptors (p, 6, K). 
Most clinically used opioids are p agonists. 
Rational Prescribing 
Initially designed as a guide for the treatment 
of cancer pain, the World Health Organization's 
analgesic ladder provides a rational basis tor pain 
management with these drugs.36 Although the 
agents are effective, many clinicians have 
reservations about administering them to treat 
chronic nonmalignant pain.32* 46, 47 Despite 
evidence to the contrary, fear of dependence 
is the major barrier to their appropriate 
pre~cription.~'. 36 Psychologic dependence is rare 
in patients receiving long-term therapy for pain 
with opioids, with frequency estimated to be 
about 0.1%.36 In one report, only four cases of 
dependence were reported among 11,882 
hospitalized patients treated with opioid 
 analgesic^.^^ 
Addiction, Physical Dependence, and Tolerance 
Confusion among addiction, physical depen- 
dence, and tolerance contributes to apprehension 
about prescribing opioids for long periods of 
time. Physical dependence to the drugs, demon- 
strated by adverse effects on sudden withdrawal, 
is a common phenomenon. However, dependence 
is not synonymous with addiction, which is 
craving for the drug.36 Long-term opioid therapy 
in patients without a history of drug dependence 
did not produce psychologic dependen~e.~'? 31v 47, 49 
Unfortunately, inappropriate prescription (e.g., 
inadequate dosages, excessively long dosage 
intervals) may create a picture of drug craving by 
patients in ~ a i n . ~ ' . ~ ~  
Tolerance is the need to increase the dosage of 
an opioid to maintain adequate analgesia.36 
However, a request for a higher dosage may not 
necessarily reflect tolerance (decreased effect of 
the drug to the same pain intensity); rather, it may 
indicate a change in pain inten~ity.~' Tolerance is 
not a clinically significant ,problem in patients 
receiving long-term opioid 49 Dosages 
remained stable for more than 80% of patients 
with cancer receiving long-term therapy3' Long- 
term therapy with little or no dosage adjustment 
also was reported by other authors,47 and a 
survey found that 60% of patients reported 
increasing their opioid dosage a little or not at all 
over time.51 Because dosage requirements can 
vary dramatically* individualized dosing is critkal. 
Adverse Effects ,' 
Common adverse effects of opioid analgesics 
occur with all agents in the class and are 
extensions of their pharmacologic effect. They 
include sedation, respiratory depression, nausea 
and vomiting, and constipation. Fortunately, 
most patients develop tolerance to sedation, 
respiratory depression, and nausea usually within 
days of starting therapy; tolerance to constipation 
is uncommon.52 Central nervous system (CNS) 
adverse effects, including sedation and confusion, 
often manifest on starting therapy or after a 
dosage increase and persist for several days to 
several weeks. If they do not subside, manage- 
ment may include discontinuing concurrent 
drugs that cause CNS effects, reducing opioid 
dosage, or adding agents such as stimulants or 
antipsychotics to counter the adverse effect.52 
Switching a patient to another opioid analgesic 
may also be effective. A series of case reports 
demonstrated that patients may have dissimilar 
side effects depending on the drug, and switching 
from one opioid to another may eliminate side 
effects and provide better analgesia.53 
The frequency of respiratory depression during 
long-term opioid therapy is reduced by two 
mechanisms. First, tolerance to the respiratory 
depression usually develops, and second, it 
appears that pain, as a respiratory stimulant, 
continues despite relief.50, *' However, dosages 
greater than those required for analgesia may 
cause clinically important respiratory depre~sion.~' 
Traditional opioids cause nausea and vomiting 
by stimulating the chemoreceptor trigger zone, 
and they also increase vertigo and delay gastric 
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emptymg. Some tolerance may develop to these 
symptoms.52. 54 Nausea and vomiting can occur 
in up to 40% of ambulatory patients.52 Persistence 
of these symptoms is usually managed by adding 
an agent to counter the mechanism of nausea. 
Metoclopramide or cisapride may relieve gastric 
stasis, meclizine or scopolamine may alleviate 
nausea related to dizziness, and prochlorperazine 
can be prescribed for other types of nausea.52 
Unfortunately, addition of these agents can be a 
particular problem in elderly patients who are 
likely to develop anticholinergic adverse effects, 
confusion, or extrapyramidal effects.' 
Constipation is experienced so often by 
patients taking long-term opioids that many 
clinicians recommend prophylactic laxatives a t  
the start of therapy.', 5 2 ,  54 Combinations of 
laxative agents may be required for maximum 
effectiveness; a stool softener is frequently 
combined with a cathartic.', 5 2  
Some opioid analgesics have distinctive adverse 
effect profiles. Pentazocine is likely to cause 
delirium and agitation in the elderlys, lo More 
than 20% of patients experience dysphoria with 
pentazocine and butorphanol; other opioids 
cause dysphoria in only about 3% of  patient^.^' 
Long-term meperidine therapy is hampered by 
production of a toxic metabolite that may cause 
agitation, tremor, or convulsions.l0, 50 As a result, 
pentazocine, butorphanol, and meperidine have 
limited application in the management of chronic 
pain in the elderly. 
Tramadol 
Tramadol, is a new synthetic, centrally acting 
analgesic with antinociceptive activity produced 
by two mechanisms: opioid receptor binding and 
inhibition of norepinephrine and serotonin 
r e ~ p t a k e . ~ ~  Both mechanisms are involved in the 
drug's analgesic action. In studies in healthy 
volunteers, the analgesic effect was only partly 
reversed by naloxone (a p opioid receptor 
a n t a g ~ n i s t ) , ~ ~  and was almost completely 
reversed by yohimbine (an a2-adrenergic receptor 
a n t a g ~ n i s t ) . ~ '  This dual action may make 
tramadol particularly effective in  treating 
neuropathic pain; however, additional studies are 
required to examine its usefulness for this 
indication. 5' 
Tramadol is effective for moderate to moderately 
severe pain; its analgesic potency is generally 
comparable to that of meperidine, pentazocine, 
and codeine,30- 59, 6o but its analgesic effect in higher 
dosages may be similar to that of morphine.32 
Adverse Effects 
Although tramadol is generally well tolerated, 
it commonly causes dizziness, nausea, vomiting, 
sedation, constipation, dry mouth, sweating, and 
headache.61 When it is administered orally, the 
frequency of nausea and dizziness is 5%, sedation 
and dry mouth 3%, and vomiting Adverse 
effects are dose related; accumulation of the drug 
can occur with repeated administration and 
dosage adjustment may be warranted, particularly 
in patients with renal or hepatic irn~airment.~', 62  
Tramadol reportedly causes less of some opioid- 
induced adverse effects, such as respiratory 
depression, urinary retention, and c~nst ipat ion.~~.  
59, 63 With long-term therapy, equianalgesic doses 
of tramadol, oxycodone with acetaminophen, 
and codeine with acetaminophen were associated 
with constipation in 35%, 41%, and 58% of patients, 
re s p e c t iv e 1 y. * After short - term in t r a v e n o u s 
administration, tramadol produced significantly 
less respiratory depression than morphine.63, 64 
Abuse Potential 
Tramadol may have less potential to cause drug 
dependence than traditional opioid analgesics; 
sensation of euphoria is uncommon. In a study 
of abuse potential, the drug was compared with 
morphine by administering each agent and 
placebo to subjects who were previously opioid 
dependent.65 Subjects were asked to describe the 
effect of each drug on three scales: feel the drug, 
high, and like the drug. Morphine significantly 
increased scores on all three scales. In contrast, 
the highest dose of tramadol (300 mg) produced 
a significant elevation only for feel the drug; the 
two lower doses (75 and 150 mg) were not 
significantly different from placebo. Another 
study examined the effect of naloxone to test for 
physical dependence in  patients who had 
received tramadol for pain relief.66 Most patients 
(94%) showed no signs of dependence; the rating 
for those who had withdrawal symptoms was 
slight to marginal. This property may make 
tramadol a good choice for the treatment of chronic 
pain. Furthermore, the agent has comparable 
efficacy to acetaminophen with codeine and is 
unlikely to induce euphoria or tolerance with 
continued use.67 Combined, these attributes 
make i t  an appropriate analgesic for the 
management of chronic pain in elderly patients. 
Antidepressants 
The antinociceptive effect of antidepressants is 
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thought to result from an intrinsic analgesic 
effect6’ rather than mood elevation.69% 70 Placebo- 
controlled studies33, 6 9 9  7 1 9  72 and two meta- 
analyses6’, 70  examined the effectiveness of 
antidepressants in the treatment of chronic pain 
conditions. The agents were less effective for the 
treatment of pain than for the treatment of 
depression; approximately 57-65% of patients 
obtained pain relief compared with 70% of those 
who usually responded to the antidepressant 
effects of these In 7047% of trials, 
antidepressants were more efficacious than 
placebo for treating 6s70 
The dosage at which analgesia occurs is lower 
than that given to treat depression, and the time 
to onset of pain relief is often shorter than that 
required for antidepressant effects.”, 68, 70, 71 The 
duration of analgesia is not well studied but is 
believed to persist with continued therapy. In 
two trials that  investigated the long-term 
analgesic efficacy of antidepressants, more than 
half of patients still experienced analgesic benefit 
after 1 year of therapy. Furthermore, a decrease 
in  dosage can be attempted 1 month after 
maximum benefit is obtained, and after 3-6 
months of therapy, slow tapering of dosage.33 
Some patients may even be able to discdntinue 
therapy and maintain pain relief.33 
Although these drugs are potentially effective 
for a wide variety of chronic pain syndromes, 
questions still arise about which conditions 
respond the best and which antidepressants may 
provide best efficacy. Some evidence suggests 
that head pain (headache, facial pain) may be 
more responsive than other types of pain33, 68; 
other conditions that may respond are 
osteoarthritis, rheumatoid arthritis, diabetic 
neuropathy, postherpetic neuralgia, low back 
pain, and fibr~myalgia.~~? 69, ’’ Both serotonin and 
adrenergic systems are probably involved in the 
perception of pain; antidepressants that  
selectively act at serotonin receptors may not be 
as effective as those that possess mixed neuro- 
transmitter activity.33, ‘*, 69 P referred drugs are 
amitriptyline, clomipramine, and doxepin.68. 70 
Adverse Effects 
Common adverse effects of tricyclic antidepres- 
sants are sedation, orthostatic hypotension, 
anticholinergic effects (dry mouth,  blurred 
vision, constipation), and cardiac conduction 
effects. Sedation may be an adverse effect in one 
patient or useful in another patient who has 
difficulty sleeping. In two trials investigating 
amitriptyline 25 mg for the treatment of chronic 
pain, the most common adverse effects were 
drowsiness (23-36%) and dry mouth 
(27-31°h).73, 74 Their frequency was dose related. 
Amitriptyline 75 mg produced drowsiness in 52% 
of patients and dry mouth in 63%; however, only 
10% of patients discontinued therapy because of 
adverse effects.73 Drowsiness (8-13Oh) and 
delirium (3-18Oh) were the two most common 
reasons for patients to discontinue therapy.33 
Orthostatic hypotension is a particular concern 
in elderly patients because it is linked to falls 
resulting in hip fractures. Measuring blood 
pressure in sitting and standing positions before 
beginning therapy and 1-2 hours after the initial 
dose can help determine if it is likely to be a 
pr~blem.’~ 
Anticholinergic adverse effects are alsp of 
concern in  the elderly who may be more 
susceptible to ,them because of age-related 
changes (e.g., slowed gastrointestinal motility) or 
concurrent drug therapy. Central anticholinergic 
effects may cause confusion or agitation, and the 
drug regimen in a disoriented elderly person 
should always be suspect. 
Cardiac conduction defects may preclude pres- 
cription of tricyclic antidepressants. However, if 
such therapy is warranted, desipramine may be 
the drug of choice. Cardiac toxicity can be 
monitored by serial electrocardiograms; widening 
of the QRS complex is a sign of the disorder. 
Table 1 summarizes adverse effects of frequently 
prescribed analgesics. 
Conclusion 
Chronic pain is frequently encountered in the 
geriatric population and can have significant 
ramifications with regard to patients’ ability to 
function and enjoy life. Drug therapy for chronic 
pain is usually long term and many agents may 
be taken concurrently. Selecting the best drug or 
drug combination for elderly patients should 
include analysis of benefits and risks. The goal is 
to increase the likelihood of benefit (relief of 
pain) and limit the risks (adverse effects) 
associated with therapy. 
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